Latest Healthcare News

SomnoMed Limited reported a solid cash flow performance for Q4 2024, with operating activities generating a net inflow of $1.525 million and ending the quarter with $18.5 million in cash reserves.

SomnoMed reports a robust 19.8% revenue increase in Q2 FY25 and updates its full-year guidance, reflecting strong demand and operational improvements amid ongoing production enhancements.

Pacific Smiles Group reports robust patient fee growth of over 9% year-on-year and reaffirms FY25 guidance, while announcing a CFO change as Genesis Capital solidifies its majority stake.

InhalerX Limited reported a negative cash flow for the December quarter despite securing a substantial $38.5 million funding facility aimed at advancing its clinical trials. The company has yet to draw on this facility, maintaining a cautious cash position as it progresses its drug development programs.

InhaleRx has locked in a $38.5 million funding deal with Clendon Biotech Capital, enabling expanded Phase 2 trials for its inhaled breakthrough cancer pain and panic disorder treatments. The company also filed a key international patent, positioning itself for a faster path to FDA approval.

Cardiex Limited has commenced U.S. deliveries of its CONNEQT Pulse arterial health monitor alongside the launch of its companion CONNEQT App, marking a pivotal expansion into the American digital health market.

Universal Biosensors has secured a Vendor Master Purchase Agreement with Chewy and launched its Petrackr veterinary glucose monitoring system on Amazon, positioning itself for significant growth in North America's online pet care market.

Talius Group reports a robust December quarter with $4.4 million revenue, positive operating cash flow, and a strategic $2.5 million capital raise, positioning the company for strong growth in 2025 amid evolving aged care legislation.

Hydrix Limited has extended its contract with Paul Hartmann AG, adding $2.8 million in revenue and reinforcing its international growth strategy.

Rhythm Biosciences reported a strong December quarter, securing a $3.2 million R&D tax incentive and completing a strategic acquisition of Genetype assets, positioning the company for commercial expansion in cancer diagnostics.

Imricor Medical Systems reports strong Q4 CY24 progress with successful FDA review, CE Mark submissions, and an 840% jump in consumables revenue, positioning the company for expanded global market penetration.

Nanosonics delivers a robust H1 FY25 trading update, reporting an 18% rise in revenue to $93.6 million and a profit before tax of $10.9 million, signaling strong momentum in its infection prevention business.